CD90 and CD110 correlate with cancer stem cell potentials in human T-acute lymphoblastic leukemia cells

Yamazaki, Hiroto; Nishida, Hayato; Iwata, Satoshi; Dang, Nam H.; Morimoto, Chikao

doi:10.1016/j.bbrc.2009.03.127

Cited by 40 publications

(22 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5-7, 14, 15). CD90 was a candidate gene of particular interest as it was the only moderately but statistically significantly upregulated surface glycoprotein (Supplementary Table S2), and also previously implicated to mark TICs of other organ types including hepatocellular carcinoma, glioblastoma, and T-acute lymphoblastic leukemia (16)(17)(18). Real-time quantitative PCR was carried out to validate this finding and results were concordant with the RNA-Seq results (Fig.…”

Section: Cd90 Expression In Escc Clinical Specimens and Cell Linessupporting

confidence: 74%

“…Furthermore, CD90 expression in ESCCs was also found to be tightly correlated with lymph node metastasis, which further lends support to our observations in the second part of our study where we found CD90 to also mark the metastatic TIC subset of ESCCs. CD90, also known as Thy-1, has previously been found to marker TIC subpopulations of hepatocellular carcinoma (16), glioma (17), and T-acute lymphoblastic leukemia (18). CD90 þ cells in these cancers were formerly found to exhibit classic cancer and stem cell-like features.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A CD90+ Tumor-Initiating Cell Population with an Aggressive Signature and Metastatic Capacity in Esophageal Cancer

et al. 2013

View full text Add to dashboard Cite

Tumor-initiating cells (TIC), also known as cancer stem cells, are regarded widely as a specific subpopulation of cells needed for cancer initiation and progression. TICs have yet to be identified in esophageal tumors that have an increasing incidence in developed countries. Here, we report a CD90 þ cell population found in esophageal squamous cell carcinoma (ESCC), which is endowed with stem cell-like properties and high tumorigenic and metastatic potential. mRNA profiling of these cells suggested pathways through which they drive tumor growth and metastasis, with deregulation of an Ets-1/MMP signaling pathway and epithelial-mesenchymal transition figuring prominently. These cells possessed higher self-renewal activity and were sufficient for tumor growth, differentiation, metastasis, and chemotherapeutic resistance. CD90 þ TICs were isolated and characterized from ESCC clinical specimens as well as ESCC cell lines. In freshly resected clinical specimens, they represented a rare cell population, the levels of which correlated with strong family histories and lymph node metastasis. Our results prompt further study of this CD90 þ population of esophageal TICs as potential therapeutic targets. Cancer Res; 73(7); 2322-32. Ó2013 AACR.

show abstract

Section: Cd90 Expression In Escc Clinical Specimens and Cell Linessupporting

confidence: 74%

Section: Discussionmentioning

confidence: 99%

A CD90+ Tumor-Initiating Cell Population with an Aggressive Signature and Metastatic Capacity in Esophageal Cancer

et al. 2013

View full text Add to dashboard Cite

show abstract

“…These findings are consistent with a very recent paper on acute myeloid leukemia that reported that, in certain samples, LIC activity was found in CD34 À cell populations. 25 This suggests that additional markers, such as the CD90 (Thy1) marker 26 or Hoechst dye exclusion, will be necessary to further purify LICs from T-ALL samples.…”

Section: Discussionmentioning

confidence: 99%

Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations

et al. 2011

View full text Add to dashboard Cite

Leukemia-initiating/repopulating cells (LICs), also named leukemic stem cells, are responsible for propagating human acute leukemia. Although they have been characterized in various leukemias, their role in T-cell acute lymphoblastic leukemia (T-ALL) is unclear. To identify and characterize LICs in T-ALL (T-LIC), we fractionated peripheral blood cell populations from patient samples by flow cytometry into three cell fractions by using two markers: CD34 (a marker of immature cells and LICs) and CD7 (a marker of early T-cell differentiation). We tested these populations in both in vitro culture assays and in vivo for growth and leukemia development in immune-deficient mice. We found LIC activity in CD7 þ cells only as CD34 þ CD7 À cells contained normal human progenitors and hematopoietic stem cells that differentiated into T, B lymphoid and myeloid cells. In contrast, CD34 þ CD7 þ cells were enriched in LICs, when compared with CD34þ cells also proliferated more upon NOTCH activation than CD34 À CD7 þ cells and were sensitive to dexamethasone and NOTCH inhibitors. These data show that CD34 and CD7 expression in human T-ALL samples help in discriminating heterogeneous cell populations endowed with different LIC activity, proliferation capacity and responses to drugs.

show abstract

“…Recently research showed its expression in thymocytes, mesenchyme stem cells, embryo haemopoietic stem cells, smooth muscle cells, and cd34+myeloma cells. Moreover, thy-1 is regarded as a tumor stem cell marker in some cancers (Chen et al, 2005;Yamazaki et al, 2009;Mercati et al, 2009;True et al, 2010). Yang et al findings suggested thy-1+/CD45+ (Donnenberg et al, 2010) hepatocarcinoma compared to thy-1-/CD45-in liver cancer possessed the ability of conspicuous neoplasia, and thy-1+/CD44+ hepatocarcinoma cells showed enhanced tendency of invasion and metastasis.…”

Section: Discussionmentioning

confidence: 99%

Up-regulation of Thy-1 Promotes Invasion and Metastasis of Hepatocarcinomas

Cheng

Jiang²,

Li³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Increasing evidence has revealed that thy-1 was a potential stem cell marker of liver cancer, but no data have been shown on how thy-1 regulates the pathophysiology of liver cancer, such as proliferation, apoptosis, invasion and migration. We previously demonstrated that thy-1 was expressed in about 1% of hepg2 cells, thy-1+ hepg2 cells, but not thy-1-, demonstrating high tumorigenesis on inoculation 0.5x10 5 cells per BACA/LA mouse after 2 months. In the present study, our results showed that higher expression of thy-1 occurs in 72% (36/50 cases) of neoplastic hepatic tissues as compared to 40% (20/50 cases) of control tissues, and the expression of thy-1 is higher in poorly differentiated liver tumors than in the well-differentiated ones. In addition, thy-1 expression was detected in 85% of blood samples from liver cancer patients, but none in normal subjects or patients with cirrhosis or hepatitis. There was a significant negative correlation between thy-1expression and E-cadherin expression (a marker of invasion and migraton), but not between thy-1 expression and AFP expression in all the liver cancer and blood samples. We further investigated the relationship between thy-1 and E-cadherin in liver cancer hepg2 cell line which was transfected with pReceiver-M29/thy-1 eukaryotic expression vector followed by aspirin treatment. Lower expression of E-cadherin but higher expressions of thy-1 were detected in hepg2 cells transfected with pReceiver-M29/thy-1. Taken together, our study suggested that thy-1 probably regulates liver cancer invasion and migration.

show abstract

CD90 and CD110 correlate with cancer stem cell potentials in human T-acute lymphoblastic leukemia cells

Cited by 40 publications

References 22 publications

A CD90+ Tumor-Initiating Cell Population with an Aggressive Signature and Metastatic Capacity in Esophageal Cancer

A CD90+ Tumor-Initiating Cell Population with an Aggressive Signature and Metastatic Capacity in Esophageal Cancer

Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations

Up-regulation of Thy-1 Promotes Invasion and Metastasis of Hepatocarcinomas

Contact Info

Product

Resources

About